Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tight glucose control may preserve insulin-making cells in type 2 diabetes

NCT ID NCT05040087

Disease control Sponsor: Foundation for Atlanta Veterans Education and Research, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This trial tests whether adjusting diabetes medications to keep blood sugar levels in the normal range can preserve the body's insulin-producing beta-cells and slow the natural worsening of type 2 diabetes. Adults aged 40 to 75 with type 2 diabetes will be assigned to either usual care guided by HbA1c or intensive care guided by self-monitored blood glucose. Researchers will compare changes in beta-cell function, blood sugar control, and diabetes-related eye and kidney complications between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intensification of diabetes medication based on self-monitored blood glucose levels
What this could lead to
If successful, this approach could help preserve the body's own insulin production and slow the worsening of type 2 diabetes, potentially reducing complications and healthcare costs.
What could go wrong
This is a relatively small study, and the intensive glucose monitoring required may be burdensome. It is not yet known whether this strategy will meaningfully preserve beta-cell function or prevent complications over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

127 people

The number who actually took part.

Started

Sep 2021

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of diabetes by OGTT * age 40-75 years * HbA1c 6.0-7.4% * 1 hr OGTT glucose \>155 mg/dl in each group Exclusion Criteria: * CVD event during the previous year * systemic glucocorticoids * bariatric surgery * stage III-IV congestive heart failure * severe angina * life expectancy \<5 years * BMI \>40 kg/m2 * pregnancy * pancreatitis * family or personal history of multiple endocrine neoplasia 2a * an estimated glomerular filtration rate \[eGFR\] of ≤50 ml/min * an alanine aminotransferase (ALT) level \>3x the upper limit of the normal range * dementia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Atlanta VA Medical Center

    Decatur, Georgia, 30033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.